General Information of Drug (ID: DM9LY4Q)

Drug Name
HuMV833 Drug Info
Synonyms Anti-VEGF antibody, Toagosei; MAb (cancer), Toagosei; SMART anti-VEGF MAb, Protein Design Labs; SMART anti-VEGF, Toagosei/PDL
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM9LY4Q

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Intedanib DMSTA36 Colorectal cancer 2B91.Z Approved [3]
Fruquintinib DMHOSCQ Colorectal cancer 2B91.Z Approved [4]
Sulfatinib DMPOTM4 Neuroendocrine cancer 2B72.1 Phase 3 [4]
KH-902 DM8VO16 Diabetic macular edema 9B71.02 Phase 3 [5]
ABP 938 DM00ACQ Neovascular age-related macular degeneration 9B78.3Z Phase 3 [6]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [7]
BAY-57-9352 DMVA5NS Gastric adenocarcinoma 2B72 Phase 2 [8]
X-82 DMW1NKO Age-related macular degeneration 9B75.0 Phase 2 [4]
Vorolanib DMIM1U9 Non-small-cell lung cancer 2C25 Phase 2 [9]
BFH-772 DMVUX1C Psoriasis vulgaris EA90 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vascular endothelial growth factor receptor (VEGFR) TTVJ1D8 NOUNIPROTAC Not Available [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012394)
2 Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93.
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
6 Clinical pipeline report, company report or official report of Amgen
7 National Cancer Institute Drug Dictionary (drug id 452042).
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
10 CA patent application no. 841416, Method of selecting therapeutic indications.